JAZZ•benzinga•May 4, 2022 at 08:13 PM

Jazz Pharma Raises FY22 Sales Guidance From $3.46B-$3.66B To $3.5B-$3.7B vs $3.58B Estimate, Adj. EPS From $16-$17 To $16.70-$17.7 vs $16.54 Estimate

No summary available.

Read the full article from the original source for complete details and context.

Article published on May 4, 2022 by benzinga